References
- Giovannoni G, Comi G, Cook S, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med. 2010 Feb;362:416–426.
- Giovannoni G, Leist T, Soelberg-Sørensen P, et al. Increase of naïve B cells, M2 macrophages and reduction of memory B/T cells during immune repopulation at 96 weeks in CLARITY assessed by immune cell deconvolution. Presented at the Annual Meeting of the European Committee on Treatment and Research in Multiple Sclerosis (ECTRIMS) 2019; Poster p. 977.
- EMA summary of product charateristics: Mavenclad® (cladribine tablets). 2020 Jan.
- Giovannoni G, Soelberg-Sørensen P, Cook S, et al. Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: results from the randomized extension trial of the CLARITY study. Mult Scler. 2018 Oct;24(12):1594–1604.
- Giovannoni G, Comi G, Rammohan K, et al. Long-term disease stability assessed by the expanded disability status scale in patients treated with cladribine tablets in the CLARITY and CLARITY extension studies. Annual Meeting of the European Committee on Treatment and Research in Multiple Sclerosis (ECTRIMS) 2019; ePoster.
- Patti F, Visconti A, Capacchione A, et al.; CLARINET-MS Study Group. Long-term effectiveness in patients previously treated with cladribine tablets: a real-world analysis of the Italian multiple sclerosis registry (CLARINET-MS). Ther Adv Neurol Disord. 2020;13:1756286420922685.
- Penner IK, Wagner T, Posevitz-Fejfár A. Design of the non-interventional, prospective study CLADQoL (CLADribineTablets – evaluation of Quality of Life). Poster P112 presented at the 91th Congress of the Deutsche Gesellschaft für Neurologie (DGN); 2018; Berlin, Germany.
- Krankheitsbezogenes Kompetenznetz Multiple Sklerose (KKNMS) Qualitätshandbuch MS/NMOSD. 2020 Jan.
- EMA summary of product charateristics: Lemtrada® (alemtuzumab). 2020 Jan.